Author

M. Muckenthaler

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Organism:human· 2 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Betz· 1 shared A. Goncalves· 1 shared A. K. Miller· 1 shared A. Kopp-Schneider· 1 shared A. Lang· 1 shared A. Pichlmair· 1 shared A. Piras· 1 shared A. Teleman· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Betz

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

RBM39 shapes innate immunity through transcriptional and splicing control of key factors of the interferon response

T.-F. Li, P. Rothhaar, A. Lang, O. Gruenvogel, O. Colasanti, S. M. Olivera Ugarte, J. Traut, A. Piras, N. Acosta-Rivero, V. Goncalves Magalhaes, E. Springer, A. Betz, H.-E. Huang, J. Park, R. Qiu, , V. Lohmann

This study identifies RBM39 as a regulator of innate immunity by controlling transcription and splicing of key interferon response factors, revealing its potential as a therapeutic target.

bioRxiv · Oct 13, 2023 · PreprintImmunology

Low level of antioxidant capacity biomarkers but not target overexpression predicts vulnerability to ROS-inducing drugs

J. Samarin, P. Fabrowski, R. Kurilov, H. Nuskova, J. Hummel-Eisenbeiss, H. Pink, N. Li, V. Weru, H. Alborzinia, U. Yildiz, L. Grob, M. Taubert, M. Czech, M. Morgen, C. Brandstaedter, , N. Gunkel

The paper identifies antioxidant-capacity biomarkers (ACBs) that predict susceptibility to ROS-inducing drugs in lung cancer cells, showing that low ACB expression correlates with nitric oxide levels, not ROS levels.

bioRxiv · Jan 17, 2023Cancer Biology